拜耳斥资40亿美元收购基因治疗公司AskBio

2020-10-26 MedSci原创 MedSci原创

AskBio的腺相关基因(AAV)治疗平台已在多种疾病中显示出潜力,包括庞贝病、帕金森病和充血性心力衰竭。

拜耳宣布斥资40亿美元收购基因治疗公司Asklepios BioPharmaceutical(AskBio),以增强其在细胞和基因治疗管线。

Jobs with Asklepios BioPharmaceutical, Inc. (AskBio)

拜耳公司将首先预付款20亿美元,以获得对AskBio基因治疗平台。除了预付款外,拜耳还将根据里程碑额外支付高达20亿美元。拜耳在今天发布的一份声明表示,预计潜在里程碑付款中的75%将在未来五年内完成。

AskBio的腺相关基因(AAV)治疗平台已在多种疾病中显示出潜力,该公司的主要研究计划专注于庞贝病、帕金森病和充血性心力衰竭。自2001年成立以来,该公司已经开发了数百个专有的第三代AAV衣壳和启动子,用于改善功效、免疫应答以及组织和器官特异性。

AAV

图片来源:AskBio

该公司的联合创始人Jude Samulski是基因疗法的先驱,他还创建了两个AskBio子公司,Bamboo Therapeutics和Chatham Therapeutics,分别专注于杜氏肌营养不良症和血友病。

原始出处:

http://www.pmlive.com/pharma_news/bayer_pays_an_initial_$2bn_for_gene_therapy_firm_askbio_1354772

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1919158, encodeId=53071919158b2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 08 12:01:02 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318502, encodeId=11a7131850264, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Wed Oct 28 14:01:02 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894933, encodeId=1592894933bb, content=学习了很不错<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/31/e28d0566f86de2a159e1850018623a0d.jpg, createdBy=62d75176163, createdName=小天要好好生活, createdTime=Tue Oct 27 21:09:40 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894730, encodeId=db38894e30e7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200827/23619d3c1e944e23a9350a54edbacb81/d195c15802ae49df9886c39d3dcf868e.jpg, createdBy=e4295413629, createdName=ms3000000956234844, createdTime=Tue Oct 27 10:02:13 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894687, encodeId=574a89468e7d, content=希望看到更多好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00074131254, createdName=13c30453m58暂无昵称, createdTime=Tue Oct 27 06:02:01 CST 2020, time=2020-10-27, status=1, ipAttribution=)]
    2021-08-08 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1919158, encodeId=53071919158b2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 08 12:01:02 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318502, encodeId=11a7131850264, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Wed Oct 28 14:01:02 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894933, encodeId=1592894933bb, content=学习了很不错<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/31/e28d0566f86de2a159e1850018623a0d.jpg, createdBy=62d75176163, createdName=小天要好好生活, createdTime=Tue Oct 27 21:09:40 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894730, encodeId=db38894e30e7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200827/23619d3c1e944e23a9350a54edbacb81/d195c15802ae49df9886c39d3dcf868e.jpg, createdBy=e4295413629, createdName=ms3000000956234844, createdTime=Tue Oct 27 10:02:13 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894687, encodeId=574a89468e7d, content=希望看到更多好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00074131254, createdName=13c30453m58暂无昵称, createdTime=Tue Oct 27 06:02:01 CST 2020, time=2020-10-27, status=1, ipAttribution=)]
    2020-10-28 ying_wu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1919158, encodeId=53071919158b2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 08 12:01:02 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318502, encodeId=11a7131850264, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Wed Oct 28 14:01:02 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894933, encodeId=1592894933bb, content=学习了很不错<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/31/e28d0566f86de2a159e1850018623a0d.jpg, createdBy=62d75176163, createdName=小天要好好生活, createdTime=Tue Oct 27 21:09:40 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894730, encodeId=db38894e30e7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200827/23619d3c1e944e23a9350a54edbacb81/d195c15802ae49df9886c39d3dcf868e.jpg, createdBy=e4295413629, createdName=ms3000000956234844, createdTime=Tue Oct 27 10:02:13 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894687, encodeId=574a89468e7d, content=希望看到更多好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00074131254, createdName=13c30453m58暂无昵称, createdTime=Tue Oct 27 06:02:01 CST 2020, time=2020-10-27, status=1, ipAttribution=)]
    2020-10-27 小天要好好生活

    学习了很不错#学习#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1919158, encodeId=53071919158b2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 08 12:01:02 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318502, encodeId=11a7131850264, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Wed Oct 28 14:01:02 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894933, encodeId=1592894933bb, content=学习了很不错<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/31/e28d0566f86de2a159e1850018623a0d.jpg, createdBy=62d75176163, createdName=小天要好好生活, createdTime=Tue Oct 27 21:09:40 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894730, encodeId=db38894e30e7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200827/23619d3c1e944e23a9350a54edbacb81/d195c15802ae49df9886c39d3dcf868e.jpg, createdBy=e4295413629, createdName=ms3000000956234844, createdTime=Tue Oct 27 10:02:13 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894687, encodeId=574a89468e7d, content=希望看到更多好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00074131254, createdName=13c30453m58暂无昵称, createdTime=Tue Oct 27 06:02:01 CST 2020, time=2020-10-27, status=1, ipAttribution=)]
    2020-10-27 ms3000000956234844

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1919158, encodeId=53071919158b2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Aug 08 12:01:02 CST 2021, time=2021-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318502, encodeId=11a7131850264, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56259, encryptionId=9a535625968, topicName=拜耳)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=11b4465, createdName=ying_wu, createdTime=Wed Oct 28 14:01:02 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894933, encodeId=1592894933bb, content=学习了很不错<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/31/e28d0566f86de2a159e1850018623a0d.jpg, createdBy=62d75176163, createdName=小天要好好生活, createdTime=Tue Oct 27 21:09:40 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894730, encodeId=db38894e30e7, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200827/23619d3c1e944e23a9350a54edbacb81/d195c15802ae49df9886c39d3dcf868e.jpg, createdBy=e4295413629, createdName=ms3000000956234844, createdTime=Tue Oct 27 10:02:13 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894687, encodeId=574a89468e7d, content=希望看到更多好药, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=00074131254, createdName=13c30453m58暂无昵称, createdTime=Tue Oct 27 06:02:01 CST 2020, time=2020-10-27, status=1, ipAttribution=)]
    2020-10-27 13c30453m58暂无昵称

    希望看到更多好药

    0

相关资讯

Cancer Gene Therapy:UNC5B能够介导膀胱癌细胞的G2/M期阻滞

在许多类型的癌症中,UNC5B是一个已知的肿瘤抑制基因。作为一个跨膜蛋白,UNC5B同样能够以P53依赖的方式诱导细胞凋亡。

Circulation:过表达PDE4B可减轻衰竭心脏的β-肾上腺素能反应和适应性重塑

cAMP水解蛋白PDE4B(磷酸二酯酶4B)是心脏肾上腺素受体刺激的关键负调节因子。PDE4B缺乏会导致Ca2+处理异常,PDE4B在压力超负荷肥大中表达减少,提示增加心脏中的PDE4B对心力衰竭有益

CDE发布《基因治疗产品药学研究与评价技术指导原则(征求意见稿)》

继今年7、8两月相继发布《免疫细胞治疗产品临床试验技术指导原则(征求意见稿)》、《溶瘤病毒类药物临床试验设计指导原则(征求意见稿)》、《人源性干细胞及其衍生细胞治疗产品临床试验技术指导原则》等指导原则

诺奖的背后:基因编辑发展史上的幕后英雄和未来发展,是魔剪还是魔鬼?!

今天,Jennifer Doudna和Emmanuelle Charpentier获得2020年诺贝尔化学奖,被很多人认为实至名归,张锋再次错过大奖,虽然有争议,但是,总的来说,理论创新是第一位的,行

Blood:AAV5基因治疗后人血浆中转基因产生的VIII因子的活性

以腺相关病毒(AAV)为基础的基因治疗可以恢复血友病A(HA)内源性因子VIII(FVIII)的表达。AAV载体通常利用B结构域缺失的FVIII转基因中的人FVIII-SQ。